100 likes | 243 Views
Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre , double - blind , placebo- controlled , randomised trial . Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators
E N D
Efficacyand safety of colchicine for treatment of multiple recurrencesof pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomisedtrial Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators CardiologyDpt. Maria Vittoria Hospital, ASLTO2, Torino, Italy Conflict of interest: None
Background Clinical trials haveshownthatlow-dose colchicine (0·5–1·0 mg daily) isefficacious and safe for treatment and prevention of acute pericarditis and first recurrences. ICAP trial CORP trial RRR 0.56 NNT=3 RRR 0.56 NNT= 4 Ann Intern Med 2011; 155: 409–14 N Engl J Med 2013; 369: 1522–28
CORP-2: Aim To assess the efficacy and safety of colchicine to treatpatients with multiple recurrences of pericarditis(≥2). COlchicine for RecurrentPericarditis-2 J CardiovascMed (Hagerstown) 2007; 8: 830–34
(0·5 mg twicedaily for 6 months for patients>70 kg or 0·5 mg once daily for patients≤ 70 kg) in addition to conventional anti-inflammatory treatment with aspirin, ibuprofen, or indometacin.
Trial profile Lancet 2014; publishedtoday
Outcomes Lancet 2014; publishedtoday
Recurrence-free Survival RR 0.49 NNT= 5 Lancet 2014; publishedtoday
Safety: side effects Lancet 2014; publishedtoday
Updatedsystematicreview on colchicine for pericarditisprevention JCardiovascMed 2014; in press
Conclusions • Colchicine added to conventional anti-inflammatory treatment significantlyreduced the rate of subsequentrecurrences of pericarditis in patients with multiple recurrences. • Takentogether with results from otherrandomisedcontrolled trials, thesefindingssuggestthat colchicine should be probablyregardedas a first-line treatment for either acute or recurrentpericarditis in the absence of contrandications.